Cognition Therapeutics, Inc. (CGTX) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Cognition Therapeutics is a clinical-stage biopharmaceutical company developing disease-modifying therapies for age-related degenerative diseases of the central nervous system (CNS) and retina. The company's lead product candidate is zervimesine (CT1812), targeting Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Revenue | $0 (No product sales) |
| Grant Income | $7,497 |
| Total Operating Expenses | $16,555 |
| Net Loss | $(8,502) |
| Cash and Cash Equivalents | $34,012 |
| Restricted Cash | $750 |
| Total Liquidity | $34,762 |
| Accumulated Deficit | $(207,149) |
| Debt | None (Only minor insurance financing liability of $78k) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased to $8.5 million for the six months ended June 30, 2026, compared to $15.2 million in the same period in 2025. This improvement was driven by a significant reduction in operating expenses.
- Expense Reduction: Total operating expenses fell by $11.2 million year-over-year. Research and Development (R&D) expenses dropped from $22.3 million to $11.2 million, primarily due to decreased Phase 2 trial activities and reduced personnel costs.
- Grant Income Decline: Grant income decreased to $7.5 million from $12.2 million in the prior year, correlating with lower reimbursable clinical trial costs incurred in 2026.
- Financing Activity: The company raised approximately $6.9 million in gross proceeds through its 2025 At-The-Market (ATM) program during the first half of 2026. The previous 2022 ATM program was terminated in December 2025, and the Lincoln Park equity line expired in March 2026.
Guidance, Outlook, and Risks
- Clinical Progress:
- Alzheimer's Disease: Enrollment concluded in December 2025 for the Phase 2 START study (545 patients). Topline results are expected after 18 months of treatment. The company has aligned with the FDA on a Phase 3 study design for patients with lower plasma p-tau217 levels.
- Dementia with Lewy Bodies (DLB): The Phase 2 SHIMMER study met its primary endpoint. An expanded access program (EAP) is ongoing. The company aligned with the FDA in May 2026 on key aspects of a pivotal study for DLB psychosis.
- Geographic Atrophy: The Phase 2 MAGNIFY study was voluntarily concluded in January 2025 after enrolling approximately 100 participants.
- Liquidity Outlook: Management believes current cash resources ($34.8 million) plus obligated NIA grant funds (~$21.6 million) are sufficient to fund operations through the fourth quarter of 2027, assuming no further usage of the 2025 ATM program.
- Risks: The company faces risks related to its ability to raise additional capital, the success of clinical trials, regulatory approvals, and the novelty of its sigma-2 receptor targeting approach. There is no assurance of profitability or future funding availability.
Investor Verification Checklist
- Grant Dependency: Verify the status and future disbursement schedule of National Institute of Aging (NIA) grants, which fund a significant portion of clinical trial costs.
- Cash Runway: Confirm the "fourth quarter of 2027" liquidity projection against actual burn rates and potential delays in clinical milestones.
- ATM Capacity: Note that $68.1 million remains available under the 2025 ATM program with Jefferies, which may be utilized if cash needs arise sooner than expected.
- Clinical Milestones: Monitor the timeline for topline results from the START study (AD) and the initiation of the pivotal DLB psychosis trial.
- Equity Dilution: Review the impact of recent equity issuances (Registered Direct Offering in Aug 2025 and ATM sales) on shareholder dilution.